Inhibition of Necrotic Actions of Nitrogen-Containing Bisphosphonates (NBPs) and Their Elimination From Bone by Etidronate (a Non-NBP): A Proposal for Possible Utilization of Etidronate as a Substitution Drug for NBPs

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 5, 2010, Pages 1043-1054

  Oizumi, Takefumi ^a   Funayama, Hiromi ^b   Yamaguchi, Kouji ^a   Yokoyama, Masayoshi ^a   Takahashi, Harue ^a   Yamamoto, Miou ^a   Kuroishi, Toshinobu ^a   Kumamoto, Hiroyuki ^a   Sasaki, Keiichi ^a   Kawamura, Hiroshi ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TSURUMI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; HYDROXYAPATITE; INTERLEUKIN 1; NITROGEN; PAMIDRONIC ACID; PRAVASTATIN; RISEDRONIC ACID; TECHNETIUM 99M; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE SCINTISCANNING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG ELIMINATION; DRUG TISSUE LEVEL; DRUG UTILIZATION; EXTERNAL EAR; FEMALE; HISTOPATHOLOGY; JAW OSTEONECROSIS; MALE; MEASUREMENT; MOUSE; NONHUMAN; OTITIS; QUANTITATIVE ANALYSIS; SCLEROSIS; TIBIA; TISSUE NECROSIS;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; EAR, EXTERNAL; ETIDRONIC ACID; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-1; MALE; MICE; MICE, INBRED BALB C; NECROSIS; OSTEONECROSIS; OSTEOSCLEROSIS; PRAVASTATIN; RADIOPHARMACEUTICALS; TECHNETIUM; TIBIA; TIME FACTORS;

EID: 77950861187     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.08.027     Document Type: Article

References (48)

1. Geddes A.D., D'Souza S.M., Ebentino F.H., et al. Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heershe N.M., and Kanis J.K. (Eds). Bone and Mineral Research/8 (1994), Elsevier Science BV, Amsterdam 265
2. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961
3. Caraglia M., Santini D., Marra M., et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13 (2006) 7
4. Adami S., Bhalla A.K., Dorizzi R., et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 41 (1987) 326
5. Siris E. Bisphosphonates and iritis. Lancet 341 (1993) 436
6. Macarol V., and Frauenfelder F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthamol 118 (1994) 220
7. Sauty A., Pecherstorfer M., Zimmer-Roth I., et al. Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18 (1996) 133
8. Fleisch H.A. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29 (1997) 56
9. Thiébaud D., Sauty A., Burckhardt P., et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61 (1997) 386
10. Munns C.F., Rauch F., Mier R.J., et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35 (2004) 231
11. Ruggiero S., Mebrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
12. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1767
13. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753
14. Pazianas M., Miller P., Blimentals W.A., et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics. Clin Ther 29 (2007) 1548
15. Shimahara M., Ariyoshi Y., Imai Y., et al. A survey of bisphosphonate-related osteomyelitis/osteonecrosis of the jaw. Jpn J Oral Surg 53 (2007) 16 (Japanese, abstract in English)
16. Novartis. Home page (October 13, 2009). http://www.novartis.co.jp/product/zom/te/te_arezom0607.html
17. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
18. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508
19. Endo Y., Nakamura N., Kikuchi T., et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 52 (1993) 248
20. Endo Y., Shibazaki M., Nakamura M., et al. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 126 (1999) 903
21. Nakamura M., Yagi H., Endo Y., et al. A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis. Br J Haematol 107 (1999) 779
22. Sugawara S., Shibazaki M., Takada H., et al. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor α in mice. Br J Pharmacol 125 (1998) 735
23. Funayama H., Mayanagi H., Takada H., et al. Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch Oral Biol 45 (2000) 787
24. Yamaguchi K., Motegi K., Iwakura Y., et al. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 130 (2000) 1646
25. Deng X., Yu Z., Funayama H., et al. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 213 (2006) 64
26. Funayama H., Ohsako M., Monma Y., et al. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcif Tissue Int 76 (2005) 448
27. Lewington V.J. Cancer therapy using bone-seeking isotopes. Phys Med Biol 41 (1996) 2027
28. Horai R., Asano M., Sudo K., et al. Production of mice deficient in genes for interleukin(IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187 (1998) 1463
29. Yu Z., Funayama H., Deng X., et al. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model. Basic Clin Pharmacol Toxicol 97 (2005) 222
30. Monma Y., Funayama H., Mayanagi H., et al. Effects of weekly administrations of alendronate + clodronate on young mouse tibia: Localized action at the proximal growth plate. Calcif Tissue Int 74 (2004) 115
31. Sasaki H., Koyama S., Yokoyama M., et al. Bone metabolic activity around dental implants under loading observed using bone scintigraphy. Int J Oral Maxillofac Implants 23 (2008) 827
32. Mönkkönen J., Koponen H.-M., and Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 65 (1989) 294
33. Deng X., Yu Z., Funayama H., et al. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells. Int Immunopharmacol 7 (2007) 152
34. Roelofs A.J., Thompson K., Gordon S., et al. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12 suppl (2006) 6222s
35. Sato M., Grasser W., Endo N., et al. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095
36. Newton C.J., Ran G., Xie Y.X., et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 174 (2002) 7
37. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320 (2004) 165
38. Gober H.-J., Kistowska M., Angman L., et al. Human T-cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197 (2003) 163
39. Thompson K., and Rogers M.J. Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro. J Bone Miner Res 19 (2004) 278
40. Kunzmann V., Bauer E., Feurle J., et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96 (2000) 384
41. Miyagawa F., Tanaka Y., Yamashita S., et al. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J Immunol 166 (2001) 5508
42. Mariani S., Muraro M., Panteleoni F., et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19 (2005) 664
43. Bürk M.R., Carena I., Donda A., et al. Functional inactivation in the whole population of human Vγ9/Vδ2 T lymphocytes induced by a nonpeptidic antagonist. J Exp Med 185 (1997) 91
44. Mestas J., and Hughes C.C.W. Of mice and not men: Differences between mouse and human immunology. J Immunol 172 (2004) 2731
45. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Investig Dermatol 126 (2006) 25
46. Mandey S.H.L., Kuijk L.M., Frenkel J., et al. A role for geranylgeranylation in interleukin-1 secretion. Arthritis Rheum 54 (2006) 3690
47. Lin J.H., Chen I.W., and Duggan D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20 (1992) 473
48. Yamaguchi K., Oizumi T., Funayama H., et al. Osteonecrosis of jawbone in 2 osteoporosis patients treated with nitrogen-containing bisphosphonate: Osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. J Oral Maxillofac Surg (2010) (in press)